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Abstract 
Hormones can regulate cardiac L-type Ca’+ channels via CAMP-dependent protein kinase (PKA) phosphorylation. However, regulation of the 
cloned L-type Ca’* channel has been difficult to demonstrate conclusively. We stably transfected a human embryonic kidney (HEK-293) cell with 
the cardiac a, and/$ subunits, then examined PKA modulation of the Ca2+ current. Although forskolin did not increase basal Ca” current, the PKA 
inhibitors, H-89 and Rp-CAMPS, could inhibit basal current. We reversed H-89 inhibition with either forskolin or okadaic acid. We conclude that 
the channel was phospho~lated under basal conditions, and that in~bition of PKA allowed dephospho~lation. These studies demonstrate that 
reversible PKA regulation of cloned Ca’* channels can be studied in HEK-293 cells. 
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Regulation of cardiac contractility by catecholamines 
is due in part to the stimulation of L-type Ca*’ channel 
activity [ 11. Despite the presence of direct G protein-Ca’+ 
channel interactions [2], most of the fi-adrenergic regula- 
tion occurs via stimulation of adenylyl cyclase, which 
leads to increases in cellular CAMP and st~ulation of 
CAMP-dependent protein kinase (PKA} activity [3]. 
Biochemical and molecular biological studies have 
shown that the cardiac L-type Ca’” channel contains at 
least 3 subunits, 01~, a S, and/I2 [4-81. Recent studies have 
demonstrated that PKA phosphorylates both 01, and j12 
[8,9]. Haase et al. [S] also showed that isoproterenol 
treatment in vivo led to the phosphorylation of /3F 
Regulation of the cloned cardiac Ca*’ channel has 
been difficult to demonstrate. This difficulty stems from 
the lack of an expression system that does not contain 
endogenous channels (or subunits). Xenopus oocytes 
contain endogenous Ca*’ channels that are regulated by 
protein kinases A and C [IO]. Furthermore, mammalian 
j? subunits can stimulate these endogenous Ca*’ channels 
up to lo-fold Ill]. In addition, both oocytes and Chinese 
hamster ovary (CHO) cells contain &, [12,13]. A second 
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complication is that a, does not form functional channels 
when expressed alone in mammalian cells, requiring co- 
expression with a /3 subunit [14,15]. 
We investigated the regulation of the cloned cardiac 
L-type Ca*” channel using human embryonic kidney cells 
(HEK-293) stably transfected with the cardiac a, and /3* 
subunit. Untransfected cells express neither mRNA of 
Ca*+ channel subunits (X. Wei, unpublished observa- 
tions) nor measurable Ca*’ currents. Transfected cells 
express large dihydropyridine-sensitive Ca*’ currents. 
We show that PKA antagonists inhibit these currents, 
and that either forskolin or okadaic acid reverse this 
inhibition. We conclude that HEK-293 cells contain en- 
dogenous kinases and phosphatases that regulate cloned 
Ca*’ channels, as observed in cardiac cardiac myocytes 
[3,1&18]. 
2. Materials and methods 
2.1. Sources 
Similar results were obtained with ~-[2-~-brom~innamyia~no)- 
ethyl]-5-isoquinolines~ onami de (H-89) purchased from three suppli- 
ers (Calbiochem., La Jolla, CA; LC Laboratories, Woburn, MA; Sei- 
kagaku, Tokyo, Japan). The Rp diastereomer of adenosine cyclic 3’,5’- 
phosphothiorate (Rp-cAMPS) and nifedipine were purchased from 
Calbiochem (La Jolla, CA). Okadaic acid (ammonium salt) was pur- 
chased from LC Laboratories (Woburn, MA). Nystatin and forskolin 
were purchased from Sigma (St. Louis, MO). 
2.2. Generation of a stably-transfected HEK-293 cell 
The cloning of the rabbit cardiac a, and rat fi2 subunits has been 
described previously [6,19]. The cDNA insert encoding the a, subunit 
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was subcloned into the expression vector pRC/CMV (Invitrogen, San 
Diego, CA). The pZ cDNA insert was subcloned into the expression 
vector p91023(b) [20]. HEK-293 cells were transfected with 1 pg a, 
cDNA and 10 pg /12 cDNA using lipofectin (GIBCO, Grand Island, 
NY). Twenty-four hours after transfection, the cells were suspended in 
MEM a medium supplemented with 0.4 g/l of G418 and 10% fetal 
bovine serum. Single colonies were isolated using cloning cylinders, 
then plated in 24 well plates. Total RNA was prepared from half the 
cells of each clone and assayed for CZ, and fiZ mRNA expression using 
polymerase chain reaction. Positive clones were analyzed for a, protein 
expression using dihydropy~dine binding assays with the ligand, 
(+)[3H]PN2~-l 10. Scatchard analysis of (+)[3H]PN20~l 10 binding to 
crude membrane preparations was performed as described previously 
[6]. Cell clone HCao1&2, which expressed 250 fmol of binding sites per 
mg of membrane protein, was selected for further study. 
2.3. Eiectrophysiological analysis 
HEK-293 cells were plated on polylysine-coated cover slips and cul- 
tured 3-5 days before electrophysiological studies. Cells were grown in 
MEM a medium supplemented with 0.4 g/l of G418, 10% horse serum, 
100 units/ml penicillin, and 100 puglrnl streptomycin. Rabbit and ferret 
cardiac ventricular myocytes were prepared as described previously 
WI. 
To minimize dialysis of the cell and Ca*+ channel rundown, we used 
the nystatin perforated patch technique [22]. Whole-cell currents were 
recorded from nystatin patches using an Axopatch 200 amplifier and 
pCLAMP software (Axon Instruments, Foster City. CA). Data were 
digitized at 2 kHz and filtered at 1 kHz or off-line. Capacitive transients 
were subtracted using a Pi4 subpulse routine. All experiments were 
performed at room temperature. Pipettes were fabricated from TW- 
150-6 capillary tubing (World Precision Instruments, Sarasota, FL), 
using a Model P-97 Flaming-Brown pipette puller (Sutter Instruments, 
Novato, CA). Pipettes were typically 0.8-l .5 MR. After gigaseal forma- 
tion, incorporation of nystatin and formation of the voltage clamp was 
monitored using the capacitive transient induced by a 5 mV test pulse. 
In addition to 6O&ml nystatin, the internal pipette solution contained 
the following (in.mM): 55 CsCl, 75 Cs,SO,, 10 MgCl,, 0.1 EGTA, 10 
HEPES. nH adiusted to 7.2 with CsOH. The external Tvrodes solution 
was the’ >ollowmg (in mM): 140 NaCI, 6 KCl, 2 &Cl,, 1 MgCI,, 
10 glucose, 5 HEPES, pH 7.4. Voltage-clamp control was usually 
achieved in 5 min, then the external solution was replaced with the 
following (in mM): 10 BaCl, (or 10 CaCl,, as noted), 140 tetraethyl~- 
monium chloride, 5 CsCl, 1 MgCl,, 5 glucose, and 10 HEPES, pH 
adjusted to 7.4 with tetraethylammonium hydroxide. The holding po- 
tential was -80 mV. 
Peak currents and exponential fits were calculated using the 
pCLAMP software program clampfit (Axon Instruments, Foster City, 
kA). Current kinetics were calculated by fitting the data with the 
followine eauation: Y = A_ + A,e-tlrac’ + A,e-t/zinact. Cell capacitance 
was me&red by integrating the charging-current during a 10 mV 
hyperpolarizing pulse followed by a 15 mV depolarizing pulse. Pooled 
data are expressed as mean f S.E. Statistical significance was analyzed 
using Student’s r-test for paired data. 
All test compounds were diluted in external solution, then perfused 
into the bath at a rate of 3-5 ml/mm. The bath was continuously 
perfused throughout the experiment. Despite the use of nystatin 
patches, there was still ~ndown of the Ba” currents. To minim& the 
contribution of this rundown all drug responses were measured 3-5 min 
after application. 
3. Results 
3.1. Electrophysiological characterization of transfected 
HEK-293 cells 
In contrast to untransfected HEK-293 cells (see 
Fig. 2C), we measured large inward currents from the 
cell line transfected with the cardiac a,[4,19] and j& sub- 
units [6], HCae&-2. We recorded these currents using 
external solutions containing 10 mM of either Ca” or 
A. HEK-293 cell B. HEK-293 cell C. ventricular mvocvte 
Fig. I. Inward currents measured using 10 mM of either Cat’ or Ba”. 
Panel A shows peak inward currents measured uring 350 ms pulses 
to various test potentials from an HEK-293 cell transfected with the 
cardiac d, and & subunits. Current traces (average of 4 recorded during 
test pulses to +15 mV) are shown in panel B. Panel C shows individual 
current traces from a ferret cardiac ventricular myocyte recorded in 
either 1 mM Ca’+ or Ba” (test potential 0 mv). 
Ba2’, and tetraethylammonium chloride to block out- 
ward I(’ currents. Fig. 1A shows peak current voltage 
relationships of a single cell in either Ca2+ or BaZ’. Typ- 
ically the inward Ba*’ currents had a voltage threshold 
of -40 mV, peaked around + 10 mV, and reversed 
around +60 mV (internal pipette solution contained Cs). 
In comparison, the peak of the Ca2+ current-voltage 
relationship was shifted approximately 15 mV to depo- 
larizing potentials. Similar shifts have been noted before 
and attributed to changes in surface potential [23]. The 
mean peak Ba2+ currents were -662 + 60 pA (n = 20, 10 
mV test potential), since the average capacitance was 81 
pF this corresponds to a current density of -8.2 pA/pF. 
Individual current traces recorded during test pulses to 
+15 mV {from the cell in Panel A) are shown in Fig. 1B. 
Currents inactivated faster and more completely when 
Ca*” was the charge carrier (Z = 68 5 6 ms, 87 + 4%) in 
comparison to Ba*’ (r = 330 + 41 ms, 39 + 3%, n = 4, 
P < 0.01). We obtained similar results in rabbit or ferret 
cardiac myocytes (Fig. 1C). Since we could measure in- 
ward currents more reliably with Ba”, we used it 
throughout the rest of this study. 
B- a$, I C. untransfected 
Fig. 2. Dihydropyridine sensitivity of currents measured in HEK-293 
cells. The response to 10pM nifedipine (Panel A) or 1 fiuM racemic BAY 
KS644 (Panel B) was measured in two different a,&transfected HEK- 
293 cells. Panel C shows that no currents can be measured in an un- 
transfected HEK-293 cell in either the absence of presence of 1 pM 
racemic BAY K8644. The currents elicited by 4 depolarizing pulses to 
+lO mV from a holding potential of -80 mV were averaged. 
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An identifying feature of L-type Ca” currents is their 
sensitivity to ‘calcium antagonists’, such as dihy- 
dropyridines. Fig. 2A shows that the dihydropyridine 
antagonist nifedipine (10 PM) almost completely 
blocked the inward Ba2’ current. Fig. 2B shows that the 
dihy~opy~dine agonist, (+) Bay K8644 (1 $M), stimu- 
lates Ba2’ currents. In contrast, we did not observe in- 
ward currents in untransfected HEK-293 cells, even in 
the presence of Bay K8644 (Fig. 2C). 
3.2. Regulation of the expressed L-type currents 
Agents that either increase protein kinase activity, or 
decrease phosphatase activity, stimulate L-type Ca” 
channel activity in a variety of cells [l]. We have previ- 
ously used forskolin, which by stimulating CAMP forma- 
tion leads to activation of PKA, to stimulate Ca2’ chan- 
nel activity 3- to 4-fold in ferret and rabbit cardiac 
myocytes [21,24]. In contrast, forskolin (2, 5, or 10 PM), 
in either the absense or presence of isobutylmethylxan- 
thine (IBMX), did not stimulate Ba2’ currents recorded 
from transfected HEK-293 cells (n = 13). 
To test the possibility that the Ca2’ channel was 
phosphorylated under basal conditions, we measured the 
effect of the selective PKA inhibitor, H-89 [25]. Addition 
of H-89 to the external solution led to a rapid inhibition 
of the Ba2+ currents. Analysis of the average dose- 
response relationship (Fig. 3A) revealed an I(&, of 76 
nM. The maximum percent inhibition of peak currents 
was 53 + 5% (2 ,&M H-89, n = 6). Current-voltage anal- 
ysis shows that inhibition occurs at most test potentials 
(Fig. 3B). 
H-89 had a more pronounced inhibition of the current 
remaining at the end of the 350 ms test pulse, 78 + 3% 
(P < 0.01). H-89 did not affect activation kinetics (ract 
control, 2.2 + 0.4 ms; H-89, 2.4 + 0.5 ms), but did affect 
the inactivation rate (zinact control, 297 + 66 ms; H-89, 
A. , I ,.,.., .,.,,, _*nl B. 2, 
Fig. 3. Ba” currents in transfected HEK-293 cells were inhibited by 
H-89. Panel A shows the percent inhibition of currents measured with 
varying concentrations of H-89. Peak inward currents were measured 
during test pulses to +lO mV every 30 s. Each data point represents the 
average of 3-10 cells (mean + S.E.). The results were obtained from a 
total of 40 cells. The average data were fit using the Hill equation, and 
used to plot the smooth line. Panel B shows the average (n = 3) peak 
current-voltage relationship obtained in either the absence (a) or pres- 
ence of I PM H-89 (v). 
I 
I___l control 
100ms 
Fig. 4. H-89 affects the inactivation rate. Currents were recorded during 
test pulses to 10 mV in the absence or presence of 1 PM H-89. Four 
traces were averaged. The currents in Panel A were resealed and plotted 
together in Panel B. 
169 f 32 ms, n = 5, P < 0.01). Consistent with the effect 
of H-89 on current amplitude at the end of the test pulse, 
H-89 inhibited the extrapolated steady-state current (A,,) 
by 76% (control, 174 ? 47 pA, H-89,42 f 15 pA, n = 5, 
P < 0.05). Current traces from a representative cell are 
shown in Fig. 4. This effect on inactivation kinetics is not 
due to errors in the voltage clamp since the observed 
inactivation rate was only weakly voltage-dependent (al- 
though current decay was only observed during pulses 
above -10 mV), and similar results were obtained using 
test potentials between 0 and +40 mV (control, 380 to 
275 ms; H-89,193 to 105 ms). Previous studies in cardiac 
myocytes showed that isoproterenol stimulation slows 
the inactivation of current through L-type Ca2’ [21]. 
To confirm that H-89 inhibited the currents by acting 
on PKA, we also studied the effect of the PKA antago- 
nist, Rp-CAMPS 1261. Addition of 5 PM Rp-CAMPS led 
to a rapid inhibition of the Ba2’ currents. This concentra- 
tion inhibited currents 54 -t 3% (n = 4), similar to the 
maximal H-89 inhibition. If these effects are due to 
dephosphorylation of the channel, then agents that in- 
crease CAMP formation or inhibit phosphatase activity 
should restore activity. 
The effect of saturating concentrations of H-89 
showed little recovery upon washout (Fig. 5). However, 
subsequent addition of forskolin (5 PM) plus IBMX 
(20 PM) dramatically stimulated the Ba2’ currents, 3.6- 
fold (+ 0.6, n = 4). The time course of one such experi- 
ment is shown in Fig. 5A, which plots the change in peak 
currents measured during +lO mV test pulses. Adding 
H-89 with forskolin blocked this stimulation (n = 4), 
then there was no stimulation of Ba” current (Fig. SB). 
However, subs~uent addition of racemic Bay K8644 
stimulated the peak currents 4.0-fold (+ 1.0, n = 4). 
Using the same protocol as in Fig. 5A, we found that 
okadaic acid (1 PM) also stimulated H-89-inhibited cur- 
rents, 2-fold (? 0.2, n = 4). This stimulation was partially 
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Fig. 5. (A) Forskolin reverses the inhibition caused by H-89. Peak 
currents were measured uring test pulses to +lO mV from a holding 
potential of -80 mV. Addition of 1 ,uM H-89, wash, and 5 PM forskolin 
plus 20 PM IBMX are indicated by the boxes. (B) H-89 blocks the 
ability of forskolin to stimulate currents. The cell was treated sequen- 
tially with the following (additions indicated by boxes): 1 PM H-89; 
control external solution (wash); 5 pM forskolin, 20 ,uM IBMX plus 
1 PM H-89; and finally 1 ,uM racemic Bay K8644. 
blocked if H-89 was added with okadaic acid (1 .Zfold 
k 0.1, n = 6). 
4. Discussion 
We found that cotransfection of the cardiac 01, with the 
cardiac p2 led to the expression of functional Ca2+ chan- 
nels in HEK-293 cells. We showed that these channels 
have Ca2+ dependent inactivation and pharmacological 
responses similar to those observed in native cardiac 
myocytes. Similar results were found using either CHO 
cells or mouse L cells, where coexpression with a /I (skel- 
etal muscle /?i) was shown to be required for functional 
channel activity [ 14,151. 
We demonstrated that H-89 was a potent inhibitor of 
channel activity. Previous studies have shown that this 
isoquinolinesulfonamide derivative is highly selective for 
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PKA [25]. In fact, the ICso observed in the present exper- 
iments (76 nM) is similar to that observed in pheochro- 
mocytoma cells (48 nM) [25]. H-89 does not block the 
Ca2’ channel directly, since Bay K8644 could still stimu- 
late activity. Further evidence is that H-89 does not 
block Ca2+ currents in rabbit cardiac myocytes [24]. Rp- 
CAMPS also inhibited basal activity. Thus, we conclude 
that the channel is phosphorylated in the basal state and 
that both H-89 and Rp-CAMPS inhibit PKA, allowing 
dephosphorylation and deactivation of the channel. 
Basal phosphorylation also explains why forskolin did 
not directly stimulate currents. In contrast, forskolin 
dramatically stimulated currents after H-89 treatment. 
We suggest hat this is due to forskolin’s ability to stim- 
ulate adenylyl cyclase activity directly, leading to in- 
creases in CAMP, followed by re-phosphorylation of the 
channel. Evidence that PKA mediates forskolin stimula- 
tion was provided by the ability of H-89 to block this 
stimulation. The ability of okadaic acid to stimulate cur- 
rents after H-89 treatment provides evidence for the in- 
volvement of a protein phosphatase. 
We have shown how agents that modulate the activity 
of PKA and protein phosphatases modulate the activity 
of the cloned cardiac Ca2’ channel expressed in HEK- 
293 cells. Similar effects of forskolin [18], okadaic acid 
[17], and Rp-CAMPS [3] have been reported for L-type 
Ca2’ channels in cardiac myocytes. The magnitude of the 
forskolin stimulation of H-89-inhibited currents is nearly 
identical to the isoproterenol stimulation observed intact 
cardiac myocytes [l]. In parallel experiments with rabbit 
and ferret cardiac myocytes, we found that H-89 had 
little effect on basal Ca” currents, but could reverse the 
stimulation by forskolin [24]. Thus, the PKA-mediated 
stimulation of cloned L-type Ca2’ channel activity in 
HEK-293 cells is similar to that observed in cardiac my- 
ocytes. The only major difference is that the expressed 
channel is phosphorylated under basal conditions. 
We conclude that HEK-293 cells provide a useful ex- 
pression system where phosphorylation of cloned Ca2’ 
channels can be studied. The advantages of these cells are 
that they do not have endogenous Ca2’ channels, they do 
not express Ca2’ channel subunits, and they contain ki- 
nases and phosphatases that modulate the activity of 
transfected Ca2’ channels. 
Recent evidence suggests there may be two modula- 
tory phosphorylation sites [27]. One site may be on 01~ 
[9,28] and the other on p2 [8]. Although our studies do 
not address this issue, we do show that HEK-293 cells 
provide an expression system where this can be studied. 
Future studies will determine if phosphorylation alters 
the single channel properties of the cloned channel as 
observed in cardiac myocytes [27,29]. 
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